What is new in ESH/ESC 2007 recommendations? Review article
Article Sidebar
Main Article Content
Abstract
Successful antihypertensive treatment plays a major role in prevention of cardiovascular events including stroke, coronary artery disease and congestive heart failure. High prevalence of hypertension and its unsuccessful control as well as considerable additional evidence on important issues related to diagnostic and treatment approaches to hypertension has become available and therefore updating of the previous guidelines has been found advisable. In this article authors review 2007 Guidelines for the Management of Arterial Hypertension prepared by The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Palatini P., Benetos A., Grassi G., Julius S., Kjeldsen S.E., Mancia G., Narkiewicz K., Parati G., Pessina A.C., Ruilope L.M., Zanchetti A. European Society of Hypertension: Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J. Hypertens. 2006, 24: 603-610.
3. Dahlof B., Sever P.S., Poulter N.R. et al. ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906.
4. Lindholm L.H., Carlberg B., Samuelsson O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005, 366:1545-53.
5. Azizi M., Webb R., Nussberger J., Hollenberg N.K.: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. 2006, 24: 243-256.
6. Narkiewicz K., Wolf J., Lopez-Jimenez F., Somers V.K.: Obstructive sleep apnea and hypertension. Curr. Cardiol. Rep. 2005, 7:435-440.
7. Bulpitt C.J., Beckett N.S., Cooke J., Dumitrascu D.L., Gil-Extremera B., Nachev C., Nunes M., Peters R., Staessen J.A., Thijs L. Hypertension in the Very Elderly Trial Working Group: Results of the pilot study for the Hypertension in the Very Elderly Trial. J. Hypertens. 2003, 21:2409-2417.